Eden Liu1, Leon Hsueh1, Hajwa Kim2, Mladen I Vidovich3. 1. Division of Cardiology, University of Illinois at Chicago, Chicago, IL. 2. The University of Illinois at Chicago, Center for Clinical and Translational Science (CCTS), Chicago, IL. 3. Division of Cardiology, University of Illinois at Chicago, Chicago, IL. Electronic address: miv@uic.edu.
Abstract
BACKGROUND: We sought to determine whether there are differences in enrolled patients' risk factors in published percutaneous coronary intervention (PCI) trials between various continents. METHODS: We systematically identified clinical trials evaluating PCI interventions through PubMed. We reviewed 701 studies between 1990 and 2014 from North America (N=135), Europe (N=403), and Asia (N=163), examining the prevalence of cardiovascular risk factors-hypertension (HTN), diabetes mellitus (DM), hyperlipidemia (HL), smoking, sex, and body mass index. We performed meta-regression with random- and mixed-effects models to compare patient baseline characteristics between continents and linear meta-regression analysis to test trends over time. RESULTS: In meta-regression with random-effects model, North American trials recruited the lowest proportion of male participants (71.32%), followed by Asian (74.41%) and European trials (76.47%; P<.0001). North American trials enrolled the highest proportion of patients with HTN (63.17%, P=.0035) and HL (63.72%, P<.0001), whereas Asia enrolled the highest proportion of DM patients (29.64%, P<.0001) and smoking (38.41%, P=.0144). When adjusting for other moderators such as publication date, body mass index, and sex in meta-regression with mixed-effects model, age was significantly positively correlated with HTN, HL, DM, and smoking (P<.001). Body mass index was significantly higher in Europe and North America than in Asia. All enrollment risk factors demonstrated (β<0.02) statistically significant temporal trends over time, except for sex. CONCLUSIONS: There are major continental differences in risk factors among patients enrolled in PCI trials from various continents. Clinical trial results may not be applicable to patient populations from another region. Published by Elsevier Inc.
BACKGROUND: We sought to determine whether there are differences in enrolled patients' risk factors in published percutaneous coronary intervention (PCI) trials between various continents. METHODS: We systematically identified clinical trials evaluating PCI interventions through PubMed. We reviewed 701 studies between 1990 and 2014 from North America (N=135), Europe (N=403), and Asia (N=163), examining the prevalence of cardiovascular risk factors-hypertension (HTN), diabetes mellitus (DM), hyperlipidemia (HL), smoking, sex, and body mass index. We performed meta-regression with random- and mixed-effects models to compare patient baseline characteristics between continents and linear meta-regression analysis to test trends over time. RESULTS: In meta-regression with random-effects model, North American trials recruited the lowest proportion of male participants (71.32%), followed by Asian (74.41%) and European trials (76.47%; P<.0001). North American trials enrolled the highest proportion of patients with HTN (63.17%, P=.0035) and HL (63.72%, P<.0001), whereas Asia enrolled the highest proportion of DMpatients (29.64%, P<.0001) and smoking (38.41%, P=.0144). When adjusting for other moderators such as publication date, body mass index, and sex in meta-regression with mixed-effects model, age was significantly positively correlated with HTN, HL, DM, and smoking (P<.001). Body mass index was significantly higher in Europe and North America than in Asia. All enrollment risk factors demonstrated (β<0.02) statistically significant temporal trends over time, except for sex. CONCLUSIONS: There are major continental differences in risk factors among patients enrolled in PCI trials from various continents. Clinical trial results may not be applicable to patient populations from another region. Published by Elsevier Inc.
Authors: Juliana C N Chan; Vasanti Malik; Weiping Jia; Takashi Kadowaki; Chittaranjan S Yajnik; Kun-Ho Yoon; Frank B Hu Journal: JAMA Date: 2009-05-27 Impact factor: 56.272
Authors: Seth W Glickman; John G McHutchison; Eric D Peterson; Charles B Cairns; Robert A Harrington; Robert M Califf; Kevin A Schulman Journal: N Engl J Med Date: 2009-02-19 Impact factor: 91.245
Authors: Kenneth W Mahaffey; Daniel M Wojdyla; Kevin Carroll; Richard C Becker; Robert F Storey; Dominick J Angiolillo; Claes Held; Christopher P Cannon; Stefan James; Karen S Pieper; Jay Horrow; Robert A Harrington; Lars Wallentin Journal: Circulation Date: 2011-06-27 Impact factor: 29.690
Authors: Mladen I Vidovich; Samip Vasaiwala; Christopher P Cannon; Eric D Peterson; David Dai; Adrian F Hernandez; Gregg C Fonarow Journal: Am Heart J Date: 2010-06 Impact factor: 4.749
Authors: Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Tullio Palmerini; Giuseppe Biondi-Zoccai; Diego Della Riva; Andrea Mariani; Manel Sabaté; Pieter C Smits; Christoph Kaiser; Fabrizio D'Ascenzo; Giacomo Frati; Massimo Mancone; Philippe Genereux; Gregg W Stone Journal: J Am Coll Cardiol Date: 2013-11-06 Impact factor: 24.094
Authors: Joel B Braunstein; Noëlle S Sherber; Steven P Schulman; Eric L Ding; Neil R Powe Journal: Medicine (Baltimore) Date: 2008-01 Impact factor: 1.889
Authors: Adam P Bress; Rikki M Tanner; Rachel Hess; Lisandro D Colantonio; Daichi Shimbo; Paul Muntner Journal: J Am Coll Cardiol Date: 2015-11-09 Impact factor: 24.094